![](/images/graphics-bg.png)
A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
Joint Authors
Fleming, Kathryn
McGuinness, James
Glen, Hilary
Spiliopoulou, Pavlina
Kipgen, David
Source
Case Reports in Oncological Medicine
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-10-03
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer.
Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation.
Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria.
Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now.
American Psychological Association (APA)
Fleming, Kathryn& McGuinness, James& Kipgen, David& Glen, Hilary& Spiliopoulou, Pavlina. 2018. A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer. Case Reports in Oncological Medicine،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1146534
Modern Language Association (MLA)
Fleming, Kathryn…[et al.]. A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer. Case Reports in Oncological Medicine No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1146534
American Medical Association (AMA)
Fleming, Kathryn& McGuinness, James& Kipgen, David& Glen, Hilary& Spiliopoulou, Pavlina. A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer. Case Reports in Oncological Medicine. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1146534
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1146534